Phio Pharmaceuticals (PHIO) Return on Capital Employed (2012 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Return on Capital Employed came in at 66.68% in Q2 2025, up 15360.0% YoY from N/an in Q2 2024, and up 21.31% on a QoQ basis from 84.75% in Q1 2025.
Phio Pharmaceuticals (PHIO) Return on Capital Employed (2012 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 14 years of Return on Capital Employed data on file, last reported at 66.68% in Q2 2025.
- Quarterly Return on Capital Employed rose 15360.0% year-over-year to 66.68% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 66.68% (up 15360.0% YoY) and the FY2024 annual result came in at 113.02%, up 146.0% from the prior year.
- Return on Capital Employed advanced to 66.68% in Q2 2025, from 84.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 36.75% in Q2 2021 to a low of 220.28% in Q2 2024.
- A 5-year average of 104.44% and a median of 88.73% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 8083 bps — and 2025, when it soared 15360 bps.
- Tracing PHIO's Return on Capital Employed over 5 years: stood at 57.52% in 2021, then slumped by 61 bps to 92.71% in 2022, then tumbled by 49 bps to 138.46% in 2023, then dropped by 11 bps to 154.33% in 2024, then surged by 57 bps to 66.68% in 2025.
- The last three Return on Capital Employed figures came in at 66.68% (Q2 2025), 84.75% (Q1 2025), and 154.33% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -66.68% |
| Mar 31, 2025 | -84.75% |
| Dec 31, 2024 | -154.33% |
| Sep 30, 2024 | -163.30% |
| Jun 30, 2024 | -220.28% |
| Mar 31, 2024 | -149.65% |
| Dec 31, 2023 | -138.46% |
| Sep 30, 2023 | -135.66% |
| Jun 30, 2023 | -144.61% |
| Mar 31, 2023 | -140.15% |
| Dec 31, 2022 | -92.71% |
| Sep 30, 2022 | -77.23% |
| Jun 30, 2022 | -68.17% |
| Mar 31, 2022 | -59.32% |
| Dec 31, 2021 | -57.52% |
| Sep 30, 2021 | -45.86% |
| Jun 30, 2021 | -36.75% |
| Mar 31, 2021 | -44.57% |
| Dec 31, 2020 | -59.44% |
| Sep 30, 2020 | -52.96% |